Home › Compare › DECXF vs ABBV
DECXF yields 3703.70% · ABBV yields 3.06%● Live data
📍 DECXF pulled ahead of the other in Year 1
Combined, DECXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DECXF + ABBV for your $10,000?
Decade Resources Ltd., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The company holds a 65% interest in the Red Cliff property in north of Stewart, British Columbia; a 100% interest in the Goat property that consists of 8 claims totaling 1210.40 hectares located in British Columbia; and an option to earn a 100% interest in the Terrace property covering 48 contiguous mineral claims situated in British Columbia. It also holds an option agreement to acquire up to 75% interest in the Del Norte property comprising 5,830.16 hectares in 13 separate claims located in east British Columbia; and a 100% interest in the Grassy property that contains approximately 830.20 hectares in 2 separate claims situated in north of Stewart, British Columbia. In addition, the company holds interests in the Premier East property, which includes approximately 600 hectares in 7 separate claims located in British Columbia; and an option agreement to acquire up to 75% interest in the Lord Nelson property comprising of 2630 hectares in 6 separate claims situated in British Columbia. The company was incorporated in 2006 and is headquartered in Stewart, Canada.
Full DECXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.